Why Is Regentis Biomaterials Stock Rising On Wednesday?

Regentis Gets Japan Patent Office Notice of Allowance For Organic Solvent‑Free Protein‑Polymer Conjugate Compositions, Covering GelrinC Manufacturing Process And Ready‑to‑Use Liquid Formulation for Articular Cartilage Repair

Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell

Regentis Biomaterials Receives European Regulatory Approval For New GelrinC Manufacturing Process

The approval comes as Regentis prepares for the commercial launch of GelrinC® in Europe, enabling the Company to manufacture commercial product using a process that increases production yield by approximately 400%,

Regentis Biomaterials Shares Halted On Circuit Breaker To The Upside, Stock now Up 787.33%